Arman Asatryan, General Medicine Student at YSMU, X Project Master at OncoDaily, shared a post on LinkedIn:
“I was honored to participate as a poster presenter at the American Society of Clinical Oncology (ASCO) Annual Meeting 2026, where I presented our research on non-small cell lung cancer (NSCLC) immunotherapy, conducted under the supervision of Elen Baloyan, MD.
In our analysis, we reviewed NSCLC immunotherapy clinical trials conducted between 2015 and 2024. Our findings revealed increasing trial termination rates over time and significant differences in success across treatment strategies, highlighting opportunities to optimize future clinical trial design.
The key message of our study is that, as the NSCLC immunotherapy landscape becomes increasingly crowded, careful trial design, appropriate patient selection, and thoughtful choice of therapeutic strategy are becoming ever more important for achieving successful clinical outcomes.
ASCO was truly the best week of my life. I am incredibly grateful to OncoDaily for giving me the opportunity to attend and present my research at ASCO26 in Chicago. It was an honor to share this experience alongside such an inspiring team. Thank you to every member of our amazing family for making this journey unforgettable.”
Other articles featuring Arman Asatryan on OncoDaily.
